Nasdaq3 Apr 2026 13:36
Anyone remember Verona Pharma? Moved from AIM to Nasdaq about 5 or 6 years ago. Raised equity and debt. Their thing was a new treatment for COPD which is a huge market. FDA approved in June 2025. They recruited over 100 salesmen and revenue commenced soon after. Not an easy sell as the doctors had to be educated on a better treatment than the existing SOC. Revenue increased monthly and the sp too. They then got an offer from Merck, full takeover , at what I believe was a gross undervaluation. So if you go it alone Scancell don't sell out too soon.